Updating targets for natural killer/T-cell lymphoma immunotherapy
Authors:
Open Access
- 25 March 2021
- journal article
- review article
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 18 (1) , 52-62
Abstract
Natural killer/T-cell lymphoma (NKTCL) is a highly invasive subtype of non-Hodgkin lymphoma, typically positive for cytoplasmic CD3, CD56, cytotoxic markers, including granzyme B and TIA1, and Epstein-Barr virus (EBV). The current treatment methods for NKTCL are associated with several drawbacks. For example, chemotherapy can lead to drug resistance, while treatment with radiotherapy alone is inadequate and results in frequent relapses. Moreover, hematopoietic stem cell transplantation exhibits limited efficacy and is not well recognized by domestic and foreign experts. In recent years, immunotherapy has shown good clinical results and has become a hot spot in cancer research. Clinical activity of targeted antibodies, such as daratumumab (anti-CD38 antibody) and brentuximab vedotin (anti-CD30 antibody), have been reported in NKTCL. Additionally, dacetuzumab and Campath-1H have demonstrated promising results. Further encouraging data have been obtained using checkpoint inhibitors. The success of these immunotherapy agents is attributed to high expression levels of programmed death-ligand 1 in NKTCL. Furthermore, anti-CCR4 monoclonal antibodies (mAbs) exert cytotoxic actions on both CCR4+ tumor cells and regulatory T cells. Depletion of these cells and the long half-life of anti-CCR4 mAbs result in enhanced induction of antitumor effector T cells. The role of IL10 in NKTCL has also been investigated. It has been proposed that exploitation of this cytokine might provide potential novel therapeutic strategies. Cellular immunotherapy with engineered cytotoxic T lymphocytes targeted against LMP1 and LMP2 has shown promising results and sustained remission. Cellular immunotherapy may be used either as maintenance therapy following initial induction chemotherapy or in cases of relapsed/refractory disease. The present review outlines the known immunotherapy targets for the treatment of NKTCL.Keywords
This publication has 100 references indexed in Scilit:
- Heat Shock Protein 90 Inhibitors Repress Latent Membrane Protein 1 (LMP1) Expression and Proliferation of Epstein-Barr Virus-Positive Natural Killer Cell LymphomaPLOS ONE, 2013
- Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantationBlood, 2012
- Extranodal Natural-Killer/T-Cell Lymphoma, Nasal TypeAdvances in Hematology, 2010
- A novel latent membrane 2 transcript expressed in Epstein-Barr virus–positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapyBlood, 2010
- Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipientsBlood, 2010
- Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapyBritish Journal of Haematology, 2009
- Suppression of EBNA1 expression inhibits growth of EBV-positive NK/T cell lymphoma cellsCancer Biology & Therapy, 2008
- Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United StatesLeukemia & Lymphoma, 2008
- NF‐κB and AP‐1 regulate activation‐dependent CD137 (4‐1BB) expression in T cellsFEBS Letters, 2003
- Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell ClonesScience, 1992